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Pérez-Schindler J, Esparza MC, McKendry J, Breen L, Philp
A, Schenk S. Overload-mediated skeletal muscle hypertrophy is not
impaired by loss of myofiber STAT3. Am J Physiol Cell Physiol 313:
C257–C261, 2017. First published June 28, 2017; doi:10.1152/
ajpcell.00100.2017.—Although the signal pathways mediating mus-
cle protein synthesis and degradation are well characterized, the
transcriptional processes modulating skeletal muscle mass and adap-
tive growth are poorly understood. Recently, studies in mouse models
of muscle wasting or acutely exercised human muscle have suggested
a potential role for the transcription factor signal transducer and
activator of transcription 3 (STAT3), in adaptive growth. Hence, in
the present study we sought to define the contribution of STAT3 to
skeletal muscle adaptive growth. In contrast to previous work, two
different resistance exercise protocols did not change STAT3 phos-
phorylation in human skeletal muscle. To directly address the role of
STAT3 in load-induced (i.e., adaptive) growth, we studied the ana-
bolic effects of 14 days of synergist ablation (SA) in skeletal muscle-
specific STAT3 knockout (mKO) mice and their floxed, wild-type
(WT) littermates. Plantaris muscle weight and fiber area in the
nonoperated leg (control; CON) was comparable between genotypes.
As expected, SA significantly increased plantaris weight, muscle fiber
cross-sectional area, and anabolic signaling in WT mice, although
interestingly, this induction was not impaired in STAT3 mKO mice.
Collectively, these data demonstrate that STAT3 is not required for
overload-mediated hypertrophy in mouse skeletal muscle.
STAT3; skeletal muscle; hypertrophy; resistance exercise
SKELETAL MUSCLE WASTING is a hallmark of several diseases,
including cancer cachexia, chronic kidney disease (CKD),
heart failure, and diabetes (4, 14). These diseases are charac-
terized by elevated levels of circulatory proinflammatory cy-
tokines, which subsequently promote skeletal muscle atrophy
(4, 14). Resistance exercise and dietary proteins are key stimuli
to offset skeletal muscle wasting, mainly by increasing the rate
of protein synthesis via phosphoinositide 3-kinase (PI3K) and
mechanistic target of rapamycin complex 1 (mTORC1) path-
ways (7, 10). Although the transcriptional mechanisms regu-
lating resistance exercise-mediated skeletal muscle hypertro-
phy are largely unknown, acute resistance exercise has been
reported to increases the activity of the transcription factor
signal transducer and activator of transcription 3 (STAT3) in
human (5, 18–20) and rat skeletal muscle (2). Moreover,
mTORC1 can activate STAT3 and promote cell survival and
growth in cancer cells (6). Taken together, these studies sug-
gest a potential role for STAT3 in adaptive growth of skeletal
muscle, though no studies have directly addressed its contri-
bution to load-induced hypertrophy. To address this gap, we
assessed the effects of 2 wk of synergist ablation (SA) on
skeletal muscle hypertrophy in mice with skeletal muscle-
specific STAT3 knockout (mKO) (21) and their floxed/wild-
type (WT) littermates. In addition, we sought to assess the
effects of different types of resistance exercise on STAT3
phosphorylation in human skeletal muscle.1
MATERIALS AND METHODS
Human study. Skeletal muscle samples were obtained from the
study recently published by McKendry et al. (9). Briefly, healthy male
volunteers performed a single session of leg press-and leg extension
resistance exercise [8 sets at 75% of one-repetition maximum (1RM)
to volitional failure] with either 1 min (n  8) or 5 min (n  8) of
interset rest. Skeletal muscle biopsies used in the present study were
obtained at rest (Pre), 0 h, and 4 h postexercise (Post). Ethical
approval was obtained through the NHS Black Country Research
Ethics Committee (13/WM/0455); the study conformed to the stan-
dards set forward by the Declaration of Helsinki (7th version).
Animals. STAT3 mKO mice were generated as previously de-
scribed (21). All experiments were performed in 11-wk-old male
mice, with floxed and Cre negative mice being the WT control mice.
Cre expression was controlled by the muscle creatine kinase promoter.
Breeding was designed such that all mice were floxed and were either
Cre positive or negative (i.e., mice were littermates). Mice were
housed under standard conditions with free access to food and water.
All experiments were approved by and conducted in accordance with
the Animal Care Program at the University of California, San Diego.
Synergist ablation. Synergist ablation (SA) surgery, which induces
overload of the plantaris, was performed as previously described (8).
Briefly, mice were anesthetized with 2.5% isoflurane under sterile
conditions, and the soleus and gastrocnemius were surgically re-
moved. The contralateral nonoperated leg was used as control (CON).
Two weeks after SA, muscles were collected from anesthetized
animals.
Address for reprint requests and other correspondence: S. Schenk, Depart-
ment of Orthopaedic Surgery, School of Medicine, University of California
San Diego, 9500 Gilman Drive MC0863, La Jolla, CA 92093 (e-mail:
sschenk@ucsd.edu).
1 This article is the topic of an Editorial Focus by Adam J. Amorese and
Espen E. Spangenburg (1).
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Immunoblotting. Plantaris homogenization and immunoblotting
were performed as previously described (13), and proteins were
detected with a primary antibody to 4E-BP1 (no. 9452, Cell Signal-
ing), p-4E-BP1T37/46 (no. 9459, Cell Signaling), Akt (no. 4691, Cell
Signaling), p-AktT308 (no. 2965, Cell Signaling), p-AktS473 (no. 4060,
Cell Signaling), p-S6S235/S236 (no. 4858, Cell Signaling), p-S6S240/S244
(no. 5364, Cell Signaling), S6 (no. 2217, Cell Signaling), p-STAT3Y705
(no. 9145, Cell Signaling), STAT3 (no. 9132, Cell Signaling), and
myostatin (ab71808, Abcam). Visualization and quantification were
performed with G:BOX Chemi XT4 imager using GeneSys and
GeneTools software (Syngene UK, Cambridge, UK).
Determination of muscle fiber cross-sectional area. Muscle cross
sections (10 m) were taken from the muscle midbelly. Sections were
first treated with 1% bovine serum albumin and normal goat and
mouse serum as blocking agents. Sections were incubated overnight
with a polyclonal anti-laminin antibody (dilution 1:1,000; Sigma, St.
Louis, MO), and then with a secondary antibody, Alexa Fluor 594
goat anti-rabbit immunoglobulin G (dilution 1:200, Life Technolo-
gies, Carlsbad, CA). Slides were mounted with a hard-set mounting
medium with DAPI (Vector, Burlingame, CA). Laminin was used to
define the fiber perimeter and facilitate fiber area quantification.
Sections were imaged with a Leica DM6000 microscope (Leica
Microsystems, Buffalo Grove, IL) equipped with a Leica DFC365 FX
camera (Leica Microsystems) using a 10 objective and DAPI and
TX2 filter sets. Fiber cross-sectional area (CSA) analysis and calcu-
lation were performed in a blinded manner with an automatic custom-
written macro in ImageJ (National Institutes of Health, Bethesda,
MD). To eliminate neurovascular structures and “optically fused”
fibers, only regions with areas between 50 m2 and 14,000 m2 with
circularity values greater than 0.3 were measured.
Statistical analysis. Values are expressed as means  SE (n  6
muscles per group). Statistical significance was determined via two-
way ANOVA with repeated measures and Bonferroni post hoc test.
Significance was considered with a P value of 0.05.
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Fig. 1. Synergist ablation (SA) increases sig-
nal transducer and activator of transcription 3
(STAT3) phosphorylation in mouse skeletal
muscle. A: relative phosphorylation and total
STAT3 protein content in mouse skeletal
muscle following 2 wk of SA (n  6 muscles
per group). WT, wild type; mKO, skeletal
muscle-specific STAT3 knockout. B: relative
STAT3 phosphorylation levels in human
skeletal muscle pre- (P), 0 h post- (0), and 4 h
post- (4) resistance exercise with either 1 or 5
min of interset rest (n  7–8 per group). All
samples were derived at the same time and
processed in parallel. Values are means 
SE. *P  0.05, **P  0.01, and ***P 
0.001.
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Fig. 2. Synergist ablation (SA) increases skeletal muscle mass and fiber size. A: absolute mass of both control (CON) and SA plantaris. B: relative mass of both
CON and SA plantaris. C: changes in average plantaris fiber cross-sectional area (CSA) following SA. D: representative images (red: laminin, blue: nuclei) and
quantification of skeletal muscle fiber size (CSA) distribution of both CON and SA plantaris (white scale bar  100 m). Values are means  SE (n 6 muscles
per group). *P  0.05, **P  0.01.
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RESULTS AND DISCUSSION
To date, the potential role of STAT3 in skeletal muscle
adaptive growth is rather descriptive, implying an association
between STAT3 activation and skeletal muscle hypertrophy (5,
18–20). To specifically define the contribution of STAT3 to
adaptive skeletal muscle growth, we subjected WT and STAT3
mKO mice to a well-established model of skeletal muscle
hypertrophy, the SA model. Chronic overload of plantaris
significantly increased (4.5-fold) p-STAT3Y705 in WT mice
(Fig. 1A). Interestingly, SA also augmented total STAT3 pro-
tein abundance in both WT and mKO mice (Fig. 1A). As we
(21) and others (16, 24) have previously observed, while
STAT3 was ~50% lower in mKO mice, STAT3 was still
detected and, consequently, led to a misleading quantification
of higher relative p-STAT3Y705 in mKO-CON mice (Fig. 1A).
However, our recent paper demonstrated that this “residual”
STAT3 protein is from nonmuscle cells, as immunoblotting of
isolated muscle fibers revealed essentially complete knockout
of STAT3 (21). Thus, we are confident that our model is
appropriate for assessing the contribution of myofibril STAT3
to adaptive growth. In fact, SA reduced the relative levels of
p-STAT3Y705 in mKO-SA as opposed to the increase observed
in WT-SA muscles (Fig. 1A). Both skeletal muscle hypertro-
phy and regeneration strongly activate STAT3 in satellite cells
(15, 17), suggesting that the nonmuscle p-STAT3Y705 detected
in mKO potentially reflects the effect of SA on this cell
population. Notably, it is possible that satellite cells are con-
tributing nonrecombined DNA (and therefore, STAT3) to the
adult myofiber, which could contribute to muscle hypertrophy.
While we cannot discount this, we previously demonstrated
that STAT3 is not present in isolated myofibers of mature
muscle from the mKO mouse (21).
To confirm that resistance exercise activates STAT3 in
human skeletal muscle (18), we compared two resistance
exercise protocols known to induce myofibrillar protein syn-
thesis and mTORC1 signaling (9). Despite the anabolic re-
sponse to resistance exercise with both 5 and 1 min of interset
rest (9), neither protocol changed p-STAT3Y705 in human
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Fig. 3. Synergist ablation (SA) promotes the activation of anabolic pathways. A–C: relative phosphorylation levels of downstream targets of phosphoinositide
3-kinase (PI3K) (AktT308), mechanistic target of rapamycin complex 2 (mTORC2) (AktS473), and mTORC1-S6K1 (S6S235/S236 and S6S240/S244) and mTORC1
(4E-BP1T37/46) in both control (CON) and SA plantaris. D: total protein levels of the procatabolic protein myostatin under CON and SA conditions. All samples
were derived at the same time and processed in parallel. Values are means  SE (n  6 muscles per group). *P  0.05, **P  0.01, and ***P  0.001.
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skeletal muscle (Fig. 1B). While this contrasts with previous
work by Trenerry et al. (18), this difference is likely due to
when muscle was sampled after exercise; we sampled muscle
immediately and 4 h postexercise, whereas Trenerry et al.
found that pSTAT3 peaked 2 h after exercise but returned to
baseline by 4 h. Our data do not rule out the activation of
STAT3 in human skeletal muscle following resistance exer-
cise; the data further suggest that STAT3 would be transiently
activated, as reported by Trenerry et al. (18).
Under control conditions, WT and mKO mice had compa-
rable plantaris mass (Fig. 2, A and B), which is consistent with
the lack of effect of STAT3 mKO or inhibition on basal body
composition and skeletal muscle mass (21, 24). Interestingly,
despite the positive role of STAT3 in skeletal muscle wasting
(16, 24), the robust increase in both absolute and relative
plantaris mass induced by SA was not impaired in STAT3
mKO mice (Fig. 2, A and B). To specifically assess hypertro-
phy, we measured average plantaris fiber size, which revealed
a comparable increase in muscle fiber CSA in WT-SA and
mKO-SA (Fig. 2C). Analysis of fiber size distribution reflected
a consistent switch toward a higher proportion of muscle fibers
with large CSA and a decrease in smaller muscle fibers (Fig.
2D). However, in line with muscle mass and average CSA
data, the effects of SA on fiber size distribution were not
different between genotypes (Fig. 2D). Interestingly, Bonetto
et al. (3) found that transient STAT3 loss of function promoted
hypertrophy both in cultured myotubes and in mouse skeletal
muscle, which the authors speculated was dependent on inter-
leukin-6 (IL-6) inhibition. Contrasting this, however, IL-6
knockout mice exhibit normal skeletal muscle fiber CSA under
basal conditions and, though not fully understood, adaptive
growth appears to be abnormal compared with wild-type mice
(15, 22). Therefore, although the effects of transient STAT3
inactivation on adaptive growth and anabolic signaling remain
to be studied, our data demonstrate that mice with chronic loss
of STAT3 have no impairments in skeletal muscle adaptations
to load-induced growth.
To understand whether canonical growth signaling in re-
sponse to SA was altered by loss of STAT3, we assessed
different PI3K and mTORC1 target proteins. SA increased
PI3K signaling in both genotypes, as reflected by higher
relative phosphorylation levels of AktT308, whereas no effect
on mTORC2-mediated AktS473 phosphorylation was observed
(Fig. 3A). Furthermore, activation of the mTORC1 pathway
was clearly reflected by higher levels of p-S6S235/S236 and
p-S6S240/S44, with comparable responses in WT-SA and
mKO-SA mice (Fig. 3B). 4E-BP1 (a direct target of mTORC1)
phosphorylation was higher in mKO-CON and trended to
increase only in WT-SA muscles (Fig. 3C). The higher p-4E-
BP1T37/46 and trend to higher p-S6S235/S236 in mKO-CON mice
suggest that STAT3 might exert a negative effect on mTORC1
activity. Besides the positive effects of mTORC1 on STAT3
transcriptional activity (6), a possible negative feedback loop
has not been fully elucidated. A mechanism for such negative
feedback potentially involves STAT3-mediated upregulation
of the tumor suppressor phosphatase and tensin homolog,
which subsequently inhibits Akt activation (23). Moreover,
IL-6-mediated activation of STAT3 is associated with inhibi-
tion of mTORC1 signaling (11). However, we did not find
changes in Akt phosphorylation; instead, our data suggest that
the enhanced 4E-BP1 and S6 phosphorylation observed in
mKO-CON does not translate into greater skeletal muscle mass
or fiber size. The possible negative feedback mediated by
STAT3 on mTORC1 signaling and its biological function
requires further investigation.
STAT3 has been shown to indirectly promote myostatin
expression and catabolic signaling in the context of skeletal
muscle wasting (24). As expected, the protein content of
myostatin was strongly reduced by SA, though without addi-
tional effects of STAT3 mKO (Fig. 3D). Moreover, similar to
studies by others (16, 24), STAT3 KO did not modify basal
myostatin protein levels in skeletal muscle (Fig. 3D). While
myostatin mRNA levels are downregulated by SA, which
implies a transcriptional regulation (12), our data suggest that
this is not mediated by STAT3.
Altogether, the present study demonstrates that under basal
conditions, genetic deletion of STAT3 does not impact skeletal
muscle mass, thus consistent with previous reports demonstrat-
ing that STAT3 does not regulate skeletal muscle mass during
development or in the absence of pathological stimuli (16, 21,
24). Furthermore, in the context of skeletal muscle hypertro-
phy, we found that STAT3 is not required for SA-mediated
activation of anabolic signaling pathways such as PI3K and
mTORC1, nor is it required for skeletal muscle adaptive
growth in healthy mice.
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